$22.1 BillionThe market capitalization is the market value of the company. It is the sum of the value of all outstanding shares.
$42.9 MillionTotal revenue in the last quarter.
$-40.2 MillionNet income is all revenues minus all expenses including taxes and interest in the last quarter.
$-1.35Earnings per share is the amount of net income that is attributed to each single share outstanding.
-Dividends per share is the amount of dividends paid out to the shareholder of a single share in the last 12 months. The percentage indicates the ratio of the company's annual dividend compared to its current price per share (stock price).
-103.64xThe price-earnings ratio is the ratio between the price per share (stock price) and the earnings per share. It indicates the percentage of the price per share (stock price) that is generated in earnings in the last 12 months.
$-39.1 MillionEarnings before interest expenses and taxes in the last quarter.
584The number of full time employees.
10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. Its integrated solutions include single cell transcriptomics, single cell genomics, single cell epigenomes, linked-reads genomics and spatial transcriptomics. The company’s products include Single Cell Gene Expression, Immune Profiling, CNV, ATAC, and Genome and Exome. 10X Genomics was founded by Serge Saxonov, Ben Hindson, Kevin D. Ness and Eduard Diviu Terradas on July 2, 2012 and is headquartered in Pleasanton, CA.
10x Genomics, Inc. (NASDAQ: TXG), a pioneer in single-cell genomics, has been eliciting significant investor interest ever since it went public more than a year ago. The biotechnology firm has […]AlphaStreet, 9 days ago
Morgan Stanley Stick to Their Buy Rating for 10x Genomics IncInvesting.com, 16 days ago
Torex Gold Resources (OTCPK:TORXF): Q3 Non-GAAP EPS of $0.59; GAAP EPS of $0.69. Revenue of $256.5M (+29.4% Y/Y) beats by $3.52M. Press ReleaseSeeking Alpha, 24 days ago